Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Daniel Levangie
AddedMar 31, 2024
UpdatedMay 31, 2026
Daniel Levangie

Daniel Levangie

Founder, Aton Partners

CrunchbaseLinkedIn

Daniel Levangie's Career

Aton Partners
Aton Partners

Boston, MA, US

Founder
Exact Sciences
Exact Sciences

Madison, WI, US

Board Member· Board
CereVasc
CereVasc

Auburndale, FL, US

CEO· C-Suite · Management
Renovia
Renovia

Boston, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Daniel Levangie's Career

Aton Partners
Aton Partners
6Boston, MA, US
Founder

Similar to Aton Partners

Bioventure PartnersBioventure PartnersChapel Hill, NC, USAdvisory, InvestmentBioventure PartnersChapel Hill, NC, US

Bioventure Partners: Investing in and advising high-impact, tech-driven life science startups.

4
MedTech Venture PartnersMedTech Venture PartnersMenlo Park, CA, USMedical Devicesest. 2015MedTech Venture PartnersMenlo Park, CA, US · est. 2015

MTVP: A VC firm specializing in seed and early-stage investments in medical device companies.

7
Partners Innovation FundPartners Innovation FundBoston, MA, USMedical Devicesest. 2007Partners Innovation FundBoston, MA, US · est. 2007

Partners Innovation Fund: Advancing medical innovations through strategic funding support.

750
Vector VenturesVector VenturesBoston, MA, USDigital Health, Medical Devicesest. 2010Vector VenturesBoston, MA, US · est. 2010

Vector Ventures: An early-stage investment fund specializing in digital health and medical devices.

5
Exact Sciences
Exact Sciences
Public$2.1B6.4k1995Madison, WI, US
Board Member· Board

Leadership at Exact Sciences

James DoyleJames DoyleBoard Member
Kevin ConroyKevin ConroyBoard Member
Anthony ShuberAnthony ShuberFounder

Similar to Exact Sciences

GeneoscopyGeneoscopySt. Louis, MO, USCancer Screening, Diagnosticsest. 2015GeneoscopySt. Louis, MO, US · est. 2015

Geneoscopy develops noninvasive colorectal cancer screening methods using stool sample biomarkers.

Series B · $112.9M175
Guardant HealthGuardant HealthPalo Alto, CA, USCancer Diagnosticsest. 2011Guardant HealthPalo Alto, CA, US · est. 2011

Guardant Health: A Palo Alto-based biotech firm providing global cancer diagnostics and sequencing services.

Public1.8k
GRAILGRAILMenlo Park, CA, USCancer Detectionest. 2016GRAILMenlo Park, CA, US · est. 2016

GRAIL, Inc., a Menlo Park-based biotech firm, specializes in early cancer detection using science and technology.

Public · $2B823
Foundation MedicineFoundation MedicineCambridge, MA, USCancer Diagnosticsest. 2010Foundation MedicineCambridge, MA, US · est. 2010

Foundation Medicine, Inc.: A U.S. genomics firm specializing in personalized cancer diagnostic technology.

Public · $96.5M662
CereVasc
CereVasc
Series A$44M142014Auburndale, FL, US
CEO· C-Suite · Management

Leadership at CereVasc

Adel MalekAdel MalekFounder
Renovia
Renovia
Series C$72.3M302016Boston, MA, US
Board Member· Board

Leadership at Renovia

Ramon Iglesias MDRamon Iglesias MDCo-Founder
Tara ButlerTara ButlerBoard Member
Rich AldrichRich AldrichBoard Member
Marc BeerMarc BeerBoard Member
Eileen MausEileen MausCEO
Adam StoneAdam StoneBoard Member

Similar to Renovia

RenalisRenalisChicago, IL, USDigital Therapeuticsest. 2017RenalisChicago, IL, US · est. 2017

Renalis: A digital health company innovating pelvic health solutions for improved outcomes.

Seed · $1.5M18
RenovionRenovionChapel Hill, NC, USPharmaceuticalsest. 2013RenovionChapel Hill, NC, US · est. 2013

RENOVION: A clinical-stage pharmaceutical firm specializing in nebulized therapy.

Series B · $29.4M9
Axena HealthAxena HealthNewton, MA, USDigital Health, HealthTechest. 2023Axena HealthNewton, MA, US · est. 2023

Axena Health: A women-led digital health firm innovating pelvic floor disorder solutions.

Private Equity · $51.8M25
RenervaRenervaPittsburgh, PA, USMedical Devicesest. 2017RenervaPittsburgh, PA, US · est. 2017

Renerva: Innovating implantable tech for enhanced peripheral nerve repair outcomes.

Pre-Seed · $4.2M9

Daniel Levangie's Similar Executives & Operators

Achmad ZakyAchmad ZakyCo-Founder · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWillix HalimWillix HalimCEO · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakBo ZhangBo ZhangCo-Founder · DiDiWILL WEI CHENGWILL WEI CHENGBoard Member · DiDi

People Similar to Daniel Levangie

David OkronglyDavid OkronglyCEO · Autonomous Medical DevicesEvan MelroseEvan MelroseBoard Member · BioventusJeff McLarenJeff McLarenBoard Member · HealthStreamDaniel GareauDaniel GareauCEO · SurgiVanceJim BrownJim BrownFounder & CEO · DurectDaniel ChainDaniel ChainBoard Member · Intellect Neurosciences